Registered title, quoted from ClinicalTrials.gov
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Guangxi Medical University Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT04376866, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 65 years; sex: all
Registered eligibility fields
Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recurrent tumor
Inclusion criterion 1
staged as rT3-4N0-1M0或rT1-4N2-3M0 (according to the 8th AJCC edition)
Inclusion criterion 2
Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1
Inclusion criterion 3
Neutrophil ≥ 1.5×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L
Inclusion criterion 4
With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN)
Inclusion criterion 5
With normal renal function test ( creatinine clearance ≥60 ml/min)
Inclusion criterion 6
Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥200IU/ml, or 1000cps/ml.
Exclusion criterion 2
Patients with positive HCV antibody.
Exclusion criterion 3
HIV positive.
Exclusion criterion 11
Male and no pregnant female
Inclusion criterion 8
Women of child-bearing potential who are pregnant or breastfeeding.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04376866, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recurrent tumor
- staged as rT3-4N0-1M0或rT1-4N2-3M0 (according to the 8th AJCC edition)
- Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1
- Neutrophil ≥ 1.5×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L
- With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN)
- With normal renal function test ( creatinine clearance ≥60 ml/min)
- sign an "informed consent form
- Male and no pregnant female
Exclusion Criteria:
- Age older than 65, or younger than 18 years old
- Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥200IU/ml, or 1000cps/ml.
- Patients with positive HCV antibody.
- Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those only need hormone replacement therapy, and skin disease (leukoderma, psoriasis, alopecia et al) who don't need systemic therapy can recruit.
- History of interstitial lung disease
- Equivalent dose more than prednisone 10mg/d or other immunosuppressive treatments within 28 days prior to signing the informed consent.
- Receive or will receive live vaccine within 30 days prior to signing the informed consent.
- Women of child-bearing potential who are pregnant or breastfeeding.
- Suffered from malignant tumors, except the carcinoma in situ, papillary thyroid carcinoma, or skin cancer (non- melanoma) within five years.
- Hypersensitivity to macromolecular protein, or to any component of triplezumab.
- HIV positive.
- Severe, uncontrolled medical conditions and infections.
- Other diseases which may influence the safety or compliance of the clinical trial, such as heart failure with symptom, unstable angina, myocardial infarction, active infections those need systemic therapy, mental illness, or their family and society factors.
Quoted from ClinicalTrials.gov, NCT04376866, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT04376866, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.